Tocilizumab

Generic Name: Tocilizumab

Brand Names: Actemra, RoActemra, Tyenne, Tofidence

Drug Type: Biotech

Chemical Formula: -

CAS Number: 375823-41-9

Unique Ingredient Identifier: I031V2H011

Background: Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...

Indication: Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...

Associated Conditions: Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis

Associated Therapies: Monotherapy

Clinical Trials

A Trial of Tocilizumab in ALS Subjects

Phase 2

Completed

Conditions: Motor Neuron Disease
ALS
Lou Gehrig's Disease
Amyotrophic Lateral Sclerosis

Interventions: Other: Placebo
Drug: Tocilizumab

First Posted Date: 2015-06-12

Last Posted Date: 2019-12-18

Lead Sponsor: Barrow Neurological Institute

Target Recruit Count: 22

Registration Number: NCT02469896

Locations: 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States

and more 2 locations

A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)

Phase 3

Completed

Conditions: Systemic Sclerosis

Interventions: Drug: Placebo
Drug: Tocilizumab

First Posted Date: 2015-05-25

Last Posted Date: 2020-03-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 212

Registration Number: NCT02453256

Locations: 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇫🇷
Hopital Claude Huriez; Internal Medicine, Lille, France
🇺🇸
Joint & Muscle Research Institute, Charlotte, North Carolina, United States

and more 80 locations

Short-Term Application of Tocilizumab Following Myocardial Infarction

Not Applicable

Completed

Conditions: Myocardial Infarction

Interventions: Drug: Placebo
Drug: Tocilizumab

First Posted Date: 2015-04-17

Last Posted Date: 2017-11-17

Lead Sponsor: Keesler Air Force Base Medical Center

Target Recruit Count: 28

Registration Number: NCT02419937

Locations: 🇺🇸
Keesler Medical Center, Keesler Air Force Base, Mississippi, United States

Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: sarilumab SAR153191 (REGN88)
Drug: tocilizumab

First Posted Date: 2015-03-31

Last Posted Date: 2016-03-28

Lead Sponsor: Sanofi

Target Recruit Count: 30

Registration Number: NCT02404558

Locations: 🇯🇵
Investigational Site Number 392001, Sendai-Shi, Japan
🇯🇵
Investigational Site Number 392002, Sendai-Shi, Japan
🇯🇵
Investigational Site Number 392003, Sendai-Shi, Japan

Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab

First Posted Date: 2015-03-30

Last Posted Date: 2019-12-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 353

Registration Number: NCT02402686

Locations: 🇭🇺
National Institute of Rheumatology and Physiotherapy; 4Th Rheumatology Department, Budapest, Hungary
🇭🇺
Budai Irgalmasrendi Kórház KHT. II. Reumatológia, Budapest, Hungary
🇭🇺
Szent Andras Reumakorhaz; Reumatologia, Heviz, Hungary

and more 15 locations

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Alemtuzumab
Drug: Etoposide
Drug: Dexamethasone
Drug: Methotrexate
Behavioral: Phone Call
Drug: Tocilizumab

First Posted Date: 2015-03-11

Last Posted Date: 2024-01-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT02385110

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

Phase 4

Terminated

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)
Drug: Abatacept
Drug: Tocilizumab

First Posted Date: 2015-02-03

Last Posted Date: 2020-10-01

Lead Sponsor: Dr. Larry W. Moreland

Target Recruit Count: 10

Registration Number: NCT02353780

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

First Posted Date: 2015-01-28

Last Posted Date: 2024-06-04

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 307

Registration Number: NCT02348216

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
University of California Los Angeles (UCLA), Santa Monica, California, United States
🇨🇦
Princess Margaret, Toronto, Ontario, Canada

and more 33 locations

A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

Phase 1

Terminated

Conditions: B-Cell Chronic Lymphocytic Leukemia

Interventions: Drug: Chlorambucil
Drug: Obinutuzumab
Drug: Placebo
Other: Standard Premedication
Drug: Tocilizumab

First Posted Date: 2015-01-12

Last Posted Date: 2021-04-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 38

Registration Number: NCT02336048

Locations: 🇪🇸
Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain
🇪🇸
Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain
🇮🇹
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica, Sant'Andrea Delle Fratte (PG), Umbria, Italy

and more 11 locations

A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: RO6958688
Drug: Tocilizumab
Drug: Obinutuzumab

First Posted Date: 2014-12-24

Last Posted Date: 2020-04-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 149

Registration Number: NCT02324257

Locations: 🇺🇸
Cedars Sinai Medical Center; Samuel-Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇪🇸
START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain
🇺🇸
Stanford University, Palo Alto, California, United States

and more 18 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy